Stockscreener 앱 받기
9.74
9.93%
0.88
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Block Trades: Can Kalaris Therapeutics Inc weather a recessionWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
How Kalaris Therapeutics Inc. stock responds to policy changesMarket Sentiment Report & Technical Pattern Based Buy Signals - Улправда
Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - Улправда
Kalaris Therapeutics raises $50M privately - MSN
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда
KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда
Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan
Kalaris Rises On Positive Early Data From Neovascular AMD Trial And $50Mln Financing Boost - Nasdaq
Kalaris reports positive early data for TH103 in AMD treatment By Investing.com - Investing.com Australia
Aspen Aerogels Announces Amendment to MidCap Credit Facility - The Manila Times
Vine Hill Capital Investment Corp. II Announces Pricing of Upsized $200 Million Initial Public Offering - The Manila Times
Future Mineral Announces Options Grant - The Manila Times
LACAHSA Board Approves $11.4M for Emergency Rental Assistance Funding, Bringing Total Measure A Prevention Investments to $29.5M in 2025 - The Manila Times
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - The Manila Times
Biotech developing eye disease drug secures $50M to fund trials to 2027 - Stock Titan
Kalaris Posts Positive Results from Macular Degeneration Drug Trial - marketscreener.com
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in nAMD - TradingView — Track All Markets
[8-K] Kalaris Therapeutics, Inc. Reports Material Event | KLRS SEC FilingForm 8-K - Stock Titan
Kalaris reports positive early data for TH103 in AMD treatment - Investing.com India
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - The Manila Times
Kalaris Therapeutics reports positive initial Phase 1a data for TH103 - marketscreener.com
Single eye injection boosts vision in early test for macular degeneration - Stock Titan
Kalaris Therapeutics, Inc. announced that it expects to receive $49.99992 million in funding - marketscreener.com
Gold hits 5 week high – More gains aheadSector-Based Investing & Free Phenomenal Trading Returns - Bollywood Helpline
Kalaris Therapeutics Earnings Notes - Trefis
4.73%
0.92%
자본화:
|
볼륨(24시간):